The EC has approved Roche’s Vabysmo, the first bispecific antibody for the eye, for two main causes of vision loss.
Roche announced on September 19, 2022 that the European Commission (EC) has approved Vabysmo (faricimab) for the treatment of neovascular or “wet” age-related macular degeneration (nDMA) and visual impairment due to edema diabetic macular (DMO). These conditions are two of the leading causes of vision loss worldwide, affecting more than 40 million people, according to a company press release.
Faricimab is currently the only injectable eye medication authorized in Europe. Treatment will begin at intervals of up to four months for people with nAMD and DME, with the potential to require fewer eye injections over time. The treatment is a bispecific antibody designed to target and inhibit two disease pathways to restore vascular stability.
“Many people with nAMD and DME struggle to keep up with the monthly eye injections and doctor visits often associated with current standards of care, and unfortunately their vision may suffer due to insufficient treatment,” said Ramin Tadayoni, head of the department of ophthalmology. , Lariboisière, Saint-Louis and Rothschild Hospitals, Paris, France, and President-Elect of the European Society of Retina Specialists (EURETINA), in the statement. “For people in Europe living with these conditions, today’s approval offers the first new mechanism for action in over a decade; one that could improve and protect their vision with fewer injections over time.